Deepe, Jr, MD
Professor of Clinical Medicine
Director of Infectious Diseases
College of Medicine
University of Cincinnati
Infectious Disease Center - Holmes Hospital
Eden and Bethesda Avenues
- Kenyon College: A.B.
- University of Cincinnati College of Medicine: M.D.
Post Graduate Training:
- 1976-1979 Resident in Internal Medicine, Southern Illinois School of Medicine
- 1979-1980 Fellow in Infectious Diseases, University of Kentucky College of Medicine
- 1980-1981 Fellow in Infectious Diseases, University of Cincinnati College of Medicine
Licensure or Certification:
- State Medical Board of Ohio, #044441
- American Board of Internal Medicine
- Subspecialty in Infectious Diseases
American Society for Microbiology
American Association for the Advancement of Science
Member, American College of Physicians
Member, American Federation for Clinical Research
International Society for Human and Animal Mycology
American Association of Immunologists
Fellow, Infectious Disease Society of America
Member, Central Society for Clinical Research
Partial List of Publications:
Klein BS and Deepe GS Jr. Blastomyces. In: Infectious Diseases 2nd edition, Ed. By S.L. Gorbach, J.G. Bartlett, and N.R. Blacklow. W. B. Saunders, Philadelphia. 1997: 2369-2375.
Allendoerfer R and Deepe GS Jr. Modulation of immune responses in murine pulmonary histoplasmosis. J. Infect. Dis. 1997; 175: 905-914.
Deepe GS Jr. Coming of age: prospects for the development of fungal vaccines. Clin Microbio. Rev. 1997; 10: 585-596.
Healy DP, RJ Dansreau, AB Dunn, CE Clendening, AW Mounts, and GS Deepe, Jr. Reduced tetracycline biovavilability caused by magnesium aluminum silicate in liquid formulation of bismuth subsalicylate. Ann Pharmacother. 1997; 31: 1460-1464.
Batanghari JW, Deepe GS, Jr., Di Cera E, and Goldman WE. Histoplasma capsulatum acquisition of calcium and expression of CBPI during intracellular parasitism. Mol. Microbiol. 1998; 27: 531-539.
Cain JA and Deepe GS, Jr. Evolution of the primary immune response to Histoplasma capsulatum in murine lung. Infect. Immun. (in press).
Mounts AW, and Deepe GS Jr. Co-infection with Cryptococcus neoformans and Blastomyces dermatitidis. J. Med. Vet. Mycol. (in press).
Allendoerfer R, and Deepe GS, Jr. Blockade of endogenous TNF-a exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J. Immunol. (in press).
Gomez FJ, Cain JA, Gibbons R, Allendoerfer R, and Deepe GS, Jr. Váa+ cells exert protection in murine pulmonary histopasmosis. (submitted).
Deepe GS, Jr., and Seder RA. Molecular and cellular determinants of immunity to Histoplasma capsulatum. (submitted).
Haglund LA and Deepe GS, Jr. Histoplasmosis Conn's Current Therapy. (submitted).
National Institutes of Health, 1986-1990
Co-investigator, Immunoregulation in Disseminated Histoplasmosis, 30% effort. Ward Bullock, principal investigator; Direct costs-$593,872
National Institutes of Health, 1986-1989
Principal Investigator, Studies of H. capsulatum-reactive Murine T Cell lines and clones, Total direct costs, $291,997; percent effort- 55%
National Institutes of Health, 1989-1994
Principal Investigator, Studies of H. capsulatum-reactive Murine T Cell lines and clones, Total direct costs-$839,519; percent effort-55%
National Institutes of Health, 1987-1992
Research Career Development Award. H. capsulatum-reactive Murine T cell clones and hybrids. Total direct costs-$254,000; Percent effort-85%
U.S.P.H.S. Grant (NIH) #PO1-AI-28392, 1990-1994. "Molecular and Cell Biology of Fungal Pathogens". Co-principal investigator on subproject 2-Interaction of H. capsulatum with human macrophages; Total direct costs-$2,577,600; percent effort-15%
National Institutes of Health, 1993-1998
Protective Antigens from Histoplasma capsulatum. Total direct Costs-$795,187; percent effort-30%
National Institutes of Health, 1994-1997
Studies of H.Capsulatum-reactive murine T cell lines and clones. Direct costs-$375,794; percent effort- 15%
National Institutes of Health, 1995-2000
Molecular pathogenesis of Pulmonary Histoplasmosis. Direct Costs-$265,165 (subcontract); percent effort-10%
VA Merit Review, 1997-2001 Molecular and Cellular Determinants of Immunity Histoplamosis. Direct costs-$398,400; percent effort- 16%
National Institutes of Health, 1997-2002
T cell receptor usage in Pulmonary Histoplasmosis. Direct Costs-$974,245; percent effort- 20%